BioSpace News Archive

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced that Julie Hambleton, M.D., the Company’s Interim President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference. Event: 39th Annual J.P. Morgan Healthcare Conference Date: January 14, 2021 12:10-12:35 pm ET About Arch Oncology A

KEY CAPITAL CORPORATION advises that it is fast becoming clear that the approach to global COVID-19 vaccination is in crisis.

CrossRoads Extremity Systems® is proud to announce the launch of its 4-D minimally-invasive DynaBunion™ Lapidus System for surgical bunion repair.

Protective face masks, since over the past few years have been more of a necessity in the industrial realm for safety and security against high-risk contaminations and accidents.

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, is commencing the new year by participating in events and activities at the annual JP Morgan Healthcare Conference. Axiom is a presenting sponsor and will be represented by several delegates at networking events for Biotech Showcase Digital on January 11-15, 2021. One of the largest of its kind,

Bureau Veritas and OPTEL partner together to launch V-TRACE, a complete and assured traceability solution for COVID-19 vaccines along the whole supply chain

ZyVersa is well positioned in the rapidly emerging inflammasome space with a highly differentiated inflammasome inhibitor, IC 100, with potential to treat a broad range of inflammatory diseases IC 100 uniquely targets ASC to inhibit multiple types of inflammasomes, blocking both initiation of the inflammatory cascade and perpetuation of tissue-damaging inflammation ZyVersa’s pipeline includes VAR 200, a phase 2a-ready cholesterol efflux mediator for treatment of orphan renal

The Global Coalition for Adaptive Research in collaboration with Kazia and Kintara, announced the activation of Kazia’s paxalisib and Kintara’s VAL-083 in GBM AGILE.

Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson, chairman and chief executive officer, will present at the 23rd Annual Needham Virtual Growth Conference on Wednesday, January 13, 2021, at 4:15 p.m. Eastern Time.

Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it has commenced an underwritten public offering of its common stock. In connection with the offering, Harpoon Therapeutics intends to grant the underwriters in the offering a 30-day option to purchase up to an additional 15 percent of the number of shares sold. Harpoon Therapeutics p